Show simple item record

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.

dc.contributor.authorMcGown, Alan T
dc.contributor.authorJayson, Gordon C
dc.contributor.authorPettit, G R
dc.contributor.authorHaran, M S
dc.contributor.authorWard, Timothy H
dc.contributor.authorCrowther, Derek
dc.date.accessioned2010-02-12T15:51:41Z
dc.date.available2010-02-12T15:51:41Z
dc.date.issued1998
dc.identifier.citationBryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. 1998, 77 (2):216-20 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid9460991
dc.identifier.urihttp://hdl.handle.net/10541/92029
dc.description.abstractThis study shows that combinations of bryostatin 1, a novel modulator of protein kinase C currently under clinical evaluation, with the anti-oestrogenic agent tamoxifen caused a large synergistic enhancement of growth inhibition in P388 cells in vitro. The growth-inhibitory effects of bryostatin 1 in the presence of non-inhibitory concentrations of tamoxifen were increased by approximately 200-fold, whereas growth inhibition by tamoxifen in the presence of non-inhibitory concentrations of bryostatin 1 were increased over 30-fold. These data have been confirmed by isobologram analysis. The precise mechanism underlying this effect is unknown, although preliminary data implicating protein kinase C is presented. The magnitude of this synergistic effect, together with evidence of clinical responses seen when these agents were given sequentially in ovarian cancer, merits further study.
dc.language.isoenen
dc.subjectLeukaemia P388en
dc.subject.meshAnimals
dc.subject.meshBryostatins
dc.subject.meshCell Division
dc.subject.meshDrug Synergism
dc.subject.meshEnzyme Activation
dc.subject.meshGrowth Inhibitors
dc.subject.meshLactones
dc.subject.meshLeukemia P388
dc.subject.meshMacrolides
dc.subject.meshMice
dc.subject.meshProtein Kinase C
dc.subject.meshStaurosporine
dc.subject.meshTamoxifen
dc.subject.meshTetradecanoylphorbol Acetate
dc.titleBryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThis study shows that combinations of bryostatin 1, a novel modulator of protein kinase C currently under clinical evaluation, with the anti-oestrogenic agent tamoxifen caused a large synergistic enhancement of growth inhibition in P388 cells in vitro. The growth-inhibitory effects of bryostatin 1 in the presence of non-inhibitory concentrations of tamoxifen were increased by approximately 200-fold, whereas growth inhibition by tamoxifen in the presence of non-inhibitory concentrations of bryostatin 1 were increased over 30-fold. These data have been confirmed by isobologram analysis. The precise mechanism underlying this effect is unknown, although preliminary data implicating protein kinase C is presented. The magnitude of this synergistic effect, together with evidence of clinical responses seen when these agents were given sequentially in ovarian cancer, merits further study.


This item appears in the following Collection(s)

Show simple item record